Ceribell
CBLL
23.63
+0.48
+2.07%
Ceribell
US · CBLL
#3313 by market cap
Listed 2024
23.63
+0.48
+2.07%
Live - 5344 symbols - heartbeat 91s ago
· 2026-10-09 19:30
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 12.37, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year +36.09% YoY
Margins
- Gross margin
- 87.89%
- Operating margin
- -65.57%
- Net margin
- -59.97%
Key ratios & quality
- Enterprise valuei
- 768.53M
- Altman Z-Scorei
- 12.37
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 25.92M | 45.23M | 65.44M | 89.06M |
| Gross profit | 21.49M | 38.16M | 56.75M | 78.27M |
| Selling & admin expenses | 50.27M | 59.21M | 82.90M | 117.53M |
| Research & development | 7.24M | 9.00M | 13.56M | 19.14M |
| Operating profit | -36.02M | -30.04M | -39.71M | -58.40M |
| Pretax profit | -37.16M | -29.45M | -40.46M | -53.41M |
| Tax | 2.00K | 11.00K | 0 | 0 |
| Net profit | -37.16M | -29.46M | -40.46M | -53.41M |
| Basic EPS | -2 | -1 | -3 | -1 |
| Diluted EPS | -1.59 | -1.26 | -3.39 | -1.46 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 20.49M | 21.20M | 22.59M | 24.78M | 26.49M | 28.10M |
| Gross profit | 18.01M | 18.68M | 19.94M | 21.64M | 23.12M | 25.94M |
| Selling & admin expenses | 27.97M | 28.78M | 29.61M | 31.18M | 37.71M | 39.17M |
| Research & development | 4.25M | 4.85M | 4.98M | 5.06M | 6.16M | 6.75M |
| Operating profit | -14.21M | -14.95M | -14.65M | -14.60M | -20.75M | -19.98M |
| Pretax profit | -12.78M | -13.64M | -13.47M | -13.53M | -19.74M | -19.27M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -12.78M | -13.64M | -13.47M | -13.53M | -19.74M | -19.27M |
| Basic EPS | 0 | 0 | 0 | 0 | -1 | -1 |
| Diluted EPS | -0.36 | -0.38 | -0.37 | -0.36 | -0.52 | -0.51 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 79.80M | 51.96M | 217.27M | 186.72M |
| Cash & ST investments | 68.24M | 34.50M | 194.37M | 159.26M |
| Inventory | 4.08M | 5.87M | 6.94M | 7.29M |
| Total assets | 86.46M | 58.92M | 225.41M | 195.80M |
| Total current liabilities | 9.86M | 21.60M | 12.99M | 19.19M |
| Short-term debt | 3.13M | 12.53M | 1.09M | 1.11M |
| Long-term debt | 12.72M | -- | 19.56M | 19.81M |
| Total liabilities | 172,856,000.00 | 171,174,000.00 | 34,247,000.00 | 40,467,000.00 |
| Total equity | -86.40M | -112.25M | 191.17M | 155.34M |
| Retained earnings | -97.03M | -126.49M | -166.94M | -220.36M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 205.42M | 199.79M | 191.81M | 186.72M | 168.91M | 157.85M |
| Cash & ST investments | 182.70M | 177.43M | 168.54M | 159.26M | 141.18M | 129.26M |
| Inventory | 6.55M | 6.00M | 6.02M | 7.29M | 6.90M | 6.74M |
| Total assets | 213.47M | 207.69M | 199.53M | 195.80M | 178.08M | 166.35M |
| Total current liabilities | 11.83M | 15.01M | 15.17M | 19.19M | 16.18M | 17.20M |
| Short-term debt | 1.12M | 1.15M | 1.18M | 1.11M | 1.14M | 1.18M |
| Long-term debt | 19.62M | 19.68M | 19.75M | 19.81M | 19.92M | 19.98M |
| Total liabilities | 32,590,000.00 | 35,534,000.00 | 35,444,000.00 | 40,467,000.00 | 37,265,000.00 | 38,035,000.00 |
| Total equity | 180.88M | 172.16M | 164.08M | 155.34M | 140.81M | 128.31M |
| Retained earnings | -179.72M | -193.36M | -206.83M | -220.36M | -240.09M | -259.36M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -32.00M | -29.16M | -35.04M | -40.81M |
| Depreciation & amortization | 497.00K | 847.00K | 1.14M | 1.34M |
| Free cash flow | -32.52M | -30.14M | -36.38M | -41.58M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 192.83M | 0 |
| Ending cash balance | 68.24M | 34.50M | 194.37M | 40.48M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -11.40M | -7.53M | -11.10M | -10.77M | -19.30M | -12.86M |
| Depreciation & amortization | 335.00K | 324.00K | 391.00K | 291.00K | 239.00K | 245.00K |
| Free cash flow | -11.68M | -7.47M | -11.47M | -10.95M | -20.12M | -12.18M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 153.36M | 40.14M | 23.74M | 40.48M | 45.25M | 32.66M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -102.53 | -30.83 |
| ROA %i | -42.99 | -40.53 | -28.46 | -25.36 |
| ROIC %i | -- | -- | -66.85 | -26.37 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -137.18 | -60.49 | -58.77 | -57.85 |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | 8.09 | 2.41 | 16.73 | 9.73 |
| Quick ratioi | 7.45 | 1.97 | 15.80 | 9.08 |
| Debt / assetsi | 21.07 | 24.11 | 9.74 | 11.38 |
| LT debt / equityi | -- | -- | 10.92 | 13.63 |
| Interest coveragei | -22.18 | -13.04 | -19.31 | -27.26 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 50.90 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -24.72 | -220.20 | -373.40 | -30.83 | -37.54 | -43.94 |
| ROA %i | -20.94 | -37.88 | -42.55 | -25.36 | -30.84 | -35.29 |
| ROIC %i | -21.06 | -107.01 | -141.22 | -26.37 | -32.02 | -37.33 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -59.67 | -61.27 | -61.02 | -57.85 | -61.56 | -62.95 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 17.36 | 13.31 | 12.65 | 9.73 | 10.44 | 9.18 |
| Quick ratioi | 16.40 | 12.64 | 11.92 | 9.08 | 9.69 | 8.45 |
| Debt / assetsi | 10.19 | 10.38 | 10.70 | 11.38 | 12.42 | 13.17 |
| LT debt / equityi | 11.41 | 11.85 | 12.29 | 13.63 | 14.90 | 16.16 |
| Interest coveragei | -21.05 | -23.99 | -26.22 | -27.26 | -31.58 | -35.38 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Electroencephalography (EEG) headbands is the largest reported line at 75.60% of revenue, across 2 reported segments.
- The next-largest line, Electroencephalography (EEG) portal and Clarity subscriptions, is a distant second at 24.40% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Electroencephalography (EEG) headbands75.60%
Electroencephalography (EEG) portal and Clarity subscriptions24.40%
Quote time 2026-10-09 19:30:04 · For reference only, not investment advice and not tailored to your situation.
Ceribell discussion 0 comments